Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.6514
Nov 20 • 12:38 PM ET Dollar change-0.1354 Percentage change(-17.21%)
Nov 19, 8:32 PMNo clear catalyst identified for SKYE 24% regular-hours drop
Index
-
Market Cap
2.88M
Enterprise Value
-1.89M
Income
-37.67M
Sales
0.00M
Book/sh
0.31
Cash/sh
1.09
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
12
IPO
Nov 26, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
2.12
P/C
0.60
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.36
Current Ratio
1.36
Debt/Eq
0.04
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-7.59
EPS next Y
-6.75
EPS next Q
-0.77
EPS this Y
42.32%
EPS next Y
-3.69%
EPS next 5Y
1.68%
EPS past 3/5Y
45.62% 28.34%
Sales past 3/5Y
- -
EPS Y/Y TTM
26.40%
Sales Y/Y TTM
-
EPS Q/Q
100.54%
Sales Q/Q
-
Insider Own
32.76%
Insider Trans
-43.48%
Inst Own
19.31%
Inst Trans
7.63%
ROA
-162.38%
ROE
-220.31%
ROIC
-2768.93%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-40.76%
SMA50
-54.77%
SMA200
-85.03%
Trades
Shs Outstand
4.42M
Shs Float
2.97M
52W High
11.04 -94.10%
52W Low
0.50 30.25%
Volatility
21.58% 21.07%
ATR (14)
0.20
RSI (14)
28.64
Beta
3.25
Rel Volume
1.47
Avg Volume
87.78K
Volume
67,198
Perf Week
-40.24%
Perf Month
-59.79%
Perf Quarter
-69.98%
Perf Half Y
-90.18%
Perf YTD
-89.14%
Perf Year
-93.49%
Perf 3Y
-95.19%
Perf 5Y
-99.45%
Perf 10Y
-99.94%
Prev Close
0.79
Price
0.65
Change %
-17.21%
Consensus
Hold
Avg. Price Target
$16.00
Implied Upside
+2,356.2%
Analysts7incl. previous ratings
Rating Distribution5 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 06, 2025Downgrade
CCraig Hallum
Buy → Hold$2+207.0%
Oct 06, 2025Downgrade
CCantor Fitzgerald
Overweight → Neutral$2+207.0%
Aug 15, 2025Initiated
EVR logoEEvercore ISI
Outperform$10+1,435.2%
Feb 28, 2025Initiated
WWilliam Blair
Outperform
Sep 30, 2024Initiated
BNS logoBScotiabank
Sector Outperform$20+2,970.3%
Sep 10, 2024Initiated
JJMP Securities
Mkt Outperform$15+2,202.7%
Jul 09, 2024Initiated
CCraig Hallum
Buy$18+2,663.3%
May 23, 2024Initiated
CCantor Fitzgerald
Overweight$21+3,123.8%
Apr 12, 2024Initiated
OPY logoOOppenheimer
Outperform$25+3,737.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab Andrew J.DirectorSep 23 '26Sale1.61119,379192,2000Sep 24 04:31 PM
Schwab Andrew J.DirectorSep 22 '26Sale1.6528,70047,3554,528Sep 24 04:31 PM
5AM Partners VII, LLC10% OwnerSep 23 '26Sale1.61119,379192,2000Sep 24 04:29 PM
5AM Partners VII, LLC10% OwnerSep 22 '26Sale1.6528,70047,3554,528Sep 24 04:29 PM
Schwab Andrew J.DirectorSep 16 '26Sale1.9133,89264,7345,616Sep 18 06:39 PM
5AM Partners VII, LLC10% OwnerSep 16 '26Sale1.9133,89264,7345,616Sep 18 06:37 PM
Schwab Andrew J.DirectorAug 18 '26Sale0.38300,000114,00055,663Aug 20 05:59 PM
Schwab Andrew J.DirectorAug 19 '26Sale0.3568,14023,84955,254Aug 20 05:59 PM
Schwab Andrew J.DirectorAug 20 '26Sale0.327,7002,46455,208Aug 20 05:59 PM
5AM Partners VII, LLC10% OwnerAug 18 '26Sale0.38300,000114,00055,663Aug 20 05:57 PM
5AM Partners VII, LLC10% OwnerAug 19 '26Sale0.3568,14023,84955,254Aug 20 05:57 PM
5AM Partners VII, LLC10% OwnerAug 20 '26Sale0.327,7002,46455,208Aug 20 05:57 PM
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the business of research and development activities related to developing medicine for obesity and metabolic diseases. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.
PresidentMr. Punit S. Dhillon B.A.